cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Landos Biopharma Inc
3 own
5 watching
Current Price
$4.27
$0.12
(2.77%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
11.66M
52-Week High
52-Week High
4.80000
52-Week Low
52-Week Low
0.21750
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization11.66M
icon52-Week High4.80000
icon52-Week Low0.21750
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Landos Biopharma Inc do?
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company s lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Read More
How much money does Landos Biopharma Inc make?
News & Events about Landos Biopharma Inc.
Globe Newswire
8 months ago
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP...
Globe Newswire
11 months ago
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the ...
Globe Newswire
11 months ago
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (Landos or the Company), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of ...
Globe Newswire
1 year ago
On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming WeeksNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today ...
Globe Newswire
1 year ago
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On ...
Frequently Asked Questions
Frequently Asked Questions
What is Landos Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Landos Biopharma Inc shares?
plus_minus_icon
How can I buy Landos Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Landos Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Landos Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Landos Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Landos Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Landos Biopharma Inc?
plus_minus_icon
What percentage is Landos Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Landos Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.27
$0.12
(2.77%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00